Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Breast Neoplasms 88Neoplasm Metastasis 8Stomach Neoplasms 5Colorectal Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Brain Neoplasms 5Pancreatic Neoplasms 4Multiple Myeloma 4HER2-positive Breast Cancer 4Urinary Bladder Neoplasms 3Prostatic Neoplasms 3Ovarian Neoplasms 3Neoplasms 3Hematologic Neoplasms 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Salivary Gland Neoplasms 2Lymphoma 2Lung Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Wilms Tumor 1Uterine Neoplasms 1Urologic Neoplasms 1Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants 1Thyroid Neoplasms 1Thrombocytosis 1Solid Tumors 1Sarcoma, Synovial 1Sarcoma 1

Interventions

Cyclophosphamide 155Dexamethasone 141Rituximab 85fludarabine 80Lenalidomide 72Cytarabine 70Bortezomib 65fludarabine phosphate 63Gemcitabine 62venetoclax 55pomalidomide 53Etoposide 53pembrolizumab 52Paclitaxel 48Cisplatin 48Carboplatin 48Peripheral Blood Stem Cell Transplantation 47Filgrastim 40Radiotherapy 39Busulfan 37Calcium Dobesilate 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 30Vincristine 29Bendamustine Hydrochloride 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Ado-Trastuzumab Emtansine × Clear all
NCT00991562 2014-11-21

IMGN901 in Combination With Lenalidomide and Dexamethasone

ImmunoGen, Inc.

Phase 1 Completed
50 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡